LUNG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LUNG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Pulmonx's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -113.43%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Pulmonx's 3-Year ROIIC % or its related term are showing as below:
The historical data trend for Pulmonx's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
3-Year ROIIC % | Get a 7-Day Free Trial | - | - | -84.75 | -162.37 | -113.43 |
Pulmonx Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
3-Year ROIIC % | Get a 7-Day Free Trial | - | -113.43 | - | - | - |
For the Medical Devices subindustry, Pulmonx's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Pulmonx's 3-Year ROIIC % falls into.
Pulmonx's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
3-Year ROIIC % | = | 3-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 3-Year Incremental Invested Capital** |
= | ( -62.5233825 (Dec. 2023) - -32.5486244 (Dec. 2020) ) | / | ( 50.73 (Dec. 2023) - 24.304 (Dec. 2020) ) | |
= | -29.9747581 | / | 26.426 | |
= | -113.43%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Pulmonx (NAS:LUNG) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Pulmonx's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
David Aaron Lehman | officer: General Counsel | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Geoffrey Beran Rose | officer: Chief Commercial Officer | 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016 |
French Glendon E. Iii | director, officer: President and CEO | 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
John Mckune | officer: Interim CFO | 46668 CRAWFORD CT., FREMONT CA 94539 |
Derrick Sung | officer: Chief Financial Officer | C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103 |
Alissa Hsu Lynch | director | 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Richard M Ferrari | director | 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050 |
Tiffany Sullivan | director | 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Boston Scientific Corp | 10 percent owner | 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Daniel P Florin | director | 56 E. BELL DRIVE, WARSAW IN 46581 |
Mead Dana G Jr. | director | 2750 SAND HILL ROAD, MENLO PARK CA 94025 |
Thomas William Burns | director | C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
Georgia Melenikiotou | director | C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416 |
Staffan Lindstrand | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
From GuruFocus
By GuruFocus News • 11-13-2024
By GlobeNewswire • 05-06-2024
By GuruFocus News • 10-31-2024
By Marketwired • 08-29-2024
By GuruFocus Research • 05-01-2024
By Marketwired • 10-16-2024
By GuruFocus Research • 05-02-2024
By GuruFocus News • 11-08-2024
By Marketwired • 07-10-2024
By GuruFocus Research • 07-31-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.